BI 655066/ABBV-066 (risankizumab) versus Ustekinumab and placebo comparators in a randomized double blind trIal for Maintenance use in Moderate to severe plaque type psoriasis (UltIMMa-1)

Trial Profile

BI 655066/ABBV-066 (risankizumab) versus Ustekinumab and placebo comparators in a randomized double blind trIal for Maintenance use in Moderate to severe plaque type psoriasis (UltIMMa-1)

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Feb 2018

At a glance

  • Drugs Risankizumab (Primary) ; Ustekinumab
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms UltIMMa-1
  • Sponsors AbbVie; Boehringer Ingelheim
  • Most Recent Events

    • 17 Feb 2018 Results published in AbbVie Media Release
    • 17 Feb 2018 According to an AbbVie media release, data from this trial will be presented at the 2018 American Academy of Dermatology Annual Meeting.
    • 26 Oct 2017 According to an AbbVie media release, Kenneth B. Gordon, M.D., professor and chair of the Department of Dermatology at the Medical College of Wisconsin and dermatologist at the Froedtert & the Medical College of Wisconsin Froedtert Hospital, is the principal investigator of the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top